Tirzepatide

Tirzepatide is a revolutionary dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. FDA-approved for both type 2 diabetes management and chronic weight management, it has demonstrated unprecedented efficacy for weight loss and metabolic health optimization. Tirzepatide works by mimicking incretin hormones that regulate blood sugar, slow gastric emptying, and reduce appetite, offering superior results compared to single-mechanism GLP-1 agonists.

• Severe Obesity Management
• Metabolic Syndrome Reversal
• Body Composition Optimization

Dramatic weight loss (15-22% body weight), superior diabetes control, reduced cardiovascular risk, improved insulin sensitivity, appetite suppression, preserved muscle mass

Dual agonist of GIP and GLP-1 receptors, glucose-dependent insulin stimulation, gastric emptying delay, glucagon suppression, central satiety signaling through hypothalamic pathways

Peak plasma concentration: 1 day. Elimination half-life: 5 days. Largely cleared by: ~25 days.

Research protocols from published literature — not dosing recommendations.

• Semaglutide — Avoid Combination: Both are GLP-1 agonists - combining increases hypoglycemia and severe GI side effect risk
• Liraglutide — Avoid Combination: Another GLP-1 agonist - dual therapy contraindicated due to additive effects
• Insulin — Monitor Combination: May require significant insulin dose reduction due to improved sensitivity and glucose control
• Metformin — Synergistic: Complementary mechanisms for diabetes management and weight loss with enhanced efficacy
• CJC-1295 — Compatible: Growth hormone support may help preserve muscle mass during rapid weight loss
• Ipamorelin — Compatible: May help maintain metabolic rate and muscle preservation during caloric restriction
• BPC-157 — Compatible: No known interactions, may support gut health and reduce GI side effects
• 5-Amino-1MQ — Compatible: NNMT inhibition may complement GLP-1 effects for enhanced metabolic optimization

Supplies:

• Tirzepatide lyophilized powder vial
• Bacteriostatic water (BAC) for injection
• Insulin syringes (0.5ml or 1ml with fine needle)
• Alcohol prep pads or wipes
• Sterile work surface or clean towel
• Refrigerator for storage (2-8°C)

1. 1Remove tirzepatide vial from refrigerator and allow to reach room temperature for 15-20 minutes to prevent condensation
2. 2Clean vial tops with alcohol wipes using circular motion from center outward, allow to air dry completely
3. 3Calculate appropriate reconstitution volume based on desired concentration using the calculator below
4. 4Draw calculated amount of bacteriostatic water into insulin syringe, ensuring no air bubbles
5. 5Insert needle into tirzepatide vial at 45-degree angle against the glass wall, NOT directly into powder
6. 6Slowly inject BAC water down the side of the vial - inject drop by drop to avoid foaming or protein degradation
7. 7Remove needle and gently swirl vial in circular motion - NEVER shake vigorously as this destroys the protein
8. 8Allow solution to sit for 2-3 minutes if any cloudiness persists, then swirl gently again until completely clear
9. 9Final solution should be completely clear and colorless - any persistent cloudiness indicates degradation
10. 10Label vial with reconstitution date and concentration, store in refrigerator at 2-8°C immediately
11. 11Use within 28 days of reconstitution, always use fresh needle for each injection, inspect for particles before use

Appetite reduction within 1-3 days of first injection. Mild to moderate nausea for first 2-4 weeks (typically improves significantly). 1-3 lbs weight loss per week during active weight loss phase. Improved blood sugar control within 1-2 weeks for diabetics. Dramatically reduced food cravings and smaller portion satisfaction. Better satiety and meal satisfaction lasting 6-7 days per injection. Possible fatigue during initial adaptation weeks. Peak weight loss effects typically seen at 16-24 weeks. Improved energy levels after initial adaptation period.

Start with lowest dose (2.5mg) and escalate gradually every 4 weeks to minimize side effects. Contraindicated with personal/family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. Monitor for signs of acute pancreatitis (severe, persistent abdominal pain radiating to the back). Significant nausea is common initially but typically improves - stay hydrated and eat smaller meals. Requires prescription and medical supervision - not available over-the-counter. Store in refrigerator between 2-8°C, never freeze or shake vigorously. May require adjustment of other diabetes medications to prevent hypoglycemia.

Start with lowest dose (2.5mg) and escalate gradually every 4 weeks to minimize side effects. Contraindicated with personal/family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. Monitor for signs of acute pancreatitis (severe, persistent abdominal pain radiating to the back). Significant nausea is common initially but typically improves - stay hydrated and eat smaller meals. Requires prescription and medical supervision - not available over-the-counter. Store in refrigerator between 2-8°C, never freeze or shake vigorously. May require adjustment of other diabetes medications to prevent hypoglycemia.

Tirzepatide should be stored at Refrigerate 2-8°C, never freeze, protect from light.